Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid

Ta Chung Chao, Dar Ren Chen, Tsu Yi Chao, Shin Cheh Chen, Dah Cherng Yeh, Hwei Chung Wang, Wen Tsung Huang, Kun Ming Rau, King Jen Chang, Tsen Long Yang, Kuan Der Lee, Cheng Jeng Tai, Ling Ming Tseng, Ming Feng Hou

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

Background: The current study aimed to examine the impact of zoledronic acid therapy on health-related quality of life (HRQoL) in Taiwanese patients with bone metastases from breast cancer. Patients and Methods: Patients with bone metastases from breast cancer who received zoledronic acid according to the standards of care were enrolled in this observational phase IV study. HRQoL was measured monthly using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (QLQ-C30) and the breast cancer-specific module (BR-23) for 24 months. Results: A total of 366 patients from 13 centers were enrolled. QLQ C-30 demonstrated that zoledronic acid improved the HRQoL in different aspects. In particular, a significant reduction of pain in the first 14 months and the 22-month follow-up was reported by patients. QLQ-BR23 indicated improved future perspective and breast symptom scores over the course of the study. Conclusion: These data confirm the HRQoL benefits and safety of zoledronic acid in Taiwanese patients with bone metastases from breast cancer.
原文英語
頁(從 - 到)5543-5548
頁數6
期刊Anticancer Research
33
發行號12
出版狀態已發佈 - 十二月 2013

ASJC Scopus subject areas

  • 癌症研究
  • 腫瘤科

指紋

深入研究「Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid」主題。共同形成了獨特的指紋。

引用此